Vertex Pharmaceuticals (VRTX) Capital Expenditures (2009 - 2026)

Vertex Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $133.4 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 227.76% year-over-year to $133.4 million; the TTM figure through Mar 2026 stood at $530.3 million (up 96.41% YoY), while the FY2025 annual figure was $437.6 million, up 46.99% from the prior year.
• Capital Expenditures was $133.4 million for Q1 2026 at Vertex Pharmaceuticals, down from $149.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $149.4 million in Q4 2025 to a low of $33.6 million in Q4 2022.
• Historically, Capital Expenditures has averaged $74.9 million across 5 years, with a median of $63.6 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Capital Expenditures slumped 45.63% in 2022, then soared 227.76% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $33.6 million in 2022, then jumped by 72.92% to $58.1 million in 2023, then surged by 59.38% to $92.6 million in 2024, then surged by 61.34% to $149.4 million in 2025, then decreased by 10.71% to $133.4 million in 2026.
• The last three Capital Expenditures figures came in at $133.4 million (Q1 2026), $149.4 million (Q4 2025), and $101.8 million (Q3 2025), per Business Quant data.